Picture loading failed.

Anti-DLL3;CD3E therapeutic antibody (Pre-made Tarlatamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tarlatamab is a half-life extended delta-like protein 3 (DLL3)/anti-CD3 bispecific T-cell engager (HLE BiTE) antibody construct, being developed by Amgen for the treatment of small cell lung cancer, neuroendocrine prostate cancer and metastatic melanoma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-552-1mg 1mg 3090
GMP-Bios-ab-552-10mg 10mg 21890
GMP-Bios-ab-552-100mg 100mg 148000
GMP-Bios-ab-552-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-DLL3;CD3E therapeutic antibody (Pre-made Tarlatamab biosimilar,Bispecific scFv)
INN Name Tarlatamab
TargetDLL3;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesAmgen
Conditions Approvedna
Conditions ActiveSmall cell lung cancer
Conditions Discontinuedna
Development TechBiTE Technology